Pharmacokinetics and safety of first-line tuberculosis drugs rifampin, isoniazid, ethambutol, and pyrazinamide during pregnancy and postpartum: results from IMPAACT P1026s

Author:

Van Schalkwyk Marije1ORCID,Bekker Adrie2,Decloedt Eric3,Wang Jiajia4,Theron Gerhard B.5,Cotton Mark F.2,Eke Ahizechukwu C.6,Cressey Tim R.7,Shapiro David E.4,Bacon Kira8,Knowles Kevin8,George Kathleen9,Browning Renee10,Chakhtoura Nahida11,Rungruengthanakit Kittipong12,Wiesner Lubbe13ORCID,Capparelli Edmund V.1415,Stek Alice M.16,Mirochnick Mark17,Best Brookie M.1415,

Affiliation:

1. Division of Adult Infectious Diseases, Department of Medicine, Family Centre for Research with Ubuntu, Stellenbosch University and Tygerberg Hospital , Cape Town, South Africa

2. Department of Pediatrics and Child Health, Family Centre for Research with Ubuntu, Stellenbosch University and Tygerberg Hospital , Cape Town, South Africa

3. Division of Clinical Pharmacology, Department of Medicine, Stellenbosch University and Tygerberg Hospital , Cape Town, South Africa

4. Department of Biostatistics, Center for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health , Boston, Massachusetts, USA

5. Department of Obstetrics and Gynecology, Stellenbosch University , Cape Town, South Africa

6. Division of Maternal Fetal Medicine and Clinical Pharmacology, Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine , Baltimore, Maryland, USA

7. AMS-PHPT Research Collaboration, Faculty of Associated Medical Sciences, Chiang Mai University , Chiang Mai, Thailand

8. Frontier Science Foundation , Amherst, New York, USA

9. FHI 360 , Durham, North Carolina, USA

10. Division of AIDS, National Institute of Allergy and Infectious Diseases, NIH , Bethesda, Maryland, USA

11. Maternal and Pediatric Infectious Disease Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) , Bethesda, Maryland, USA

12. Research Institute for Health Sciences, Chiang Mai University , Chiang Mai, Thailand

13. Division of Clinical Pharmacology, Department of Medicine, University of Cape Town , Cape Town, South Africa

14. Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California , San Diego, California, USA

15. Department of Pediatrics, School of Medicine, University of California , San Diego, California, USA

16. Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, University of Southern California School of Medicine , Los Angeles, California, USA

17. Division of Neonatology, Department of Pediatrics, Boston University Chobanian & Avedisian School of Medicine , Boston, Massachusetts, USA

Abstract

ABSTRACT Physiological changes during pregnancy may alter the pharmacokinetics (PK) of antituberculosis drugs. The International Maternal Pediatric Adolescent AIDS Clinical Trials Network P1026s was a multicenter, phase IV, observational, prospective PK and safety study of antiretroviral and antituberculosis drugs administered as part of clinical care in pregnant persons living with and without HIV. We assessed the effects of pregnancy on rifampin, isoniazid, ethambutol, and pyrazinamide PK in pregnant and postpartum (PP) persons without HIV treated for drug-susceptible tuberculosis disease. Daily antituberculosis treatment was prescribed following World Health Organization-recommended weight-band dosing guidelines. Steady-state 12-hour PK profiles of rifampin, isoniazid, ethambutol, and pyrazinamide were performed during second trimester (2T), third trimester (3T), and 2–8 of weeks PP. PK parameters were characterized using noncompartmental analysis, and comparisons were made using geometric mean ratios (GMRs) with 90% confidence intervals (CI). Twenty-seven participants were included: 11 African, 9 Asian, 3 Hispanic, and 4 mixed descent. PK data were available for 17, 21, and 14 participants in 2T, 3T, and PP, respectively. Rifampin and pyrazinamide AUC 0–24 and C max in pregnancy were comparable to PP with the GMR between 0.80 and 1.25. Compared to PP, isoniazid AUC 0–24 was 25% lower and C max was 23% lower in 3T. Ethambutol AUC 0–24 was 39% lower in 3T but limited by a low PP sample size. In summary, isoniazid and ethambutol concentrations were lower during pregnancy compared to PP concentrations, while rifampin and pyrazinamide concentrations were similar. However, the median AUC 0–24 for rifampin, isoniazid, and pyrazinamide met the therapeutic targets. The clinical impact of lower isoniazid and ethambutol exposure during pregnancy needs to be determined.

Funder

HHS | NIH | National Institute of Allergy and Infectious Diseases

HHS | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3